Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells

Cancer Immunology Immunotherapy

Volumn 47, Issue 1, 1998, Pages 32-38

  Li, Kun ^a,c   Adibzadeh, Medi ^a   Halder, Thomas ^a   Kalbacher, Hubert ^a   Heinzel, Susanne ^a   Müller, Claudia ^a   Zeuthen, Jesper ^b   Pawelec, Graham ^a,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c MEDICAL COLLEGE OF OHIO   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Apoptosis; HLA DR restricted tumour antigens; Melanoma; Synthetic peptide antigens; Tumour escape from immune responses

Indexed keywords

ANNEXIN; EPITOPE; GLYCOPROTEIN; HLA DR3 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CYTOLYSIS; HLA SYSTEM; HOST CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKEMIA; MELANOMA; PRIORITY JOURNAL; SARCOMA; T LYMPHOCYTE ACTIVATION;

EID: 0031690656     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050501     Document Type: Article

References (42)

1. Alderson MR, Tough TW, Davis-Smith T, et al (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181:71
2. Bachmann MF, Sebzda E, Kundig TM, et al (1996) T cell responses are governed by avidity and co-stimulatory thresholds. Eur J Immunol 26:2017
3. Cheever MA, Disis ML, Bernhard H, et al (1995) Immunity to oncogenic proteins. Immunol Rev 145:33-59
4. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G (1993) Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pm1/RARalpha present in acute promyelocytic leukemia cells. Blood 81:1369
5. Gedde-Dahl T, Fossum B, Eriksen JA, Thorsby E, Gaudernack G (1993) T-cell clones specific for p21 ras-derived peptides characterization of their fine specificity and HLA Restriction. Eur J Immunol 23:754
6. Gjertsen MK, Bakka A, Breivik J, et al (1996) Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 65:450
7. Gjertsen MK, Saeterdal I, Thorsby E, Gaudernack G (1996) Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. Br J Cancer 74:1828
8. Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G (1997) Cytotoxic CD4(+) and CD8(+) T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 72:784
9. Guilloux Y, Viret C, Gervois N, et al (1994) Defective lymphokine production by most CD8(+) and CD4(+) tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol 24:1966
10. Hahne M, Rimoldi D, Schroter M, et al (1996) Melanoma cell expression of Fas(Apo-I/CD95) ligand: Implications for tumor immune escape. Science 274:1363
11. Halder T, Pawelec G, Kirkin AF, et al (1997) Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 57:3238
12. Hammer J, Valsasnini P, Tolba K, et al (1993) Promiscuous and allele-specific anchors in HLA-DR-binding peptidcs. Cell 74:197
13. Heike M, Schlaak J, Schulzebergkamen H, et al (1996) Specificities and functions of CD4(+) HLA class II-restricled T cell clones against a human sarcoma evidence for several recognized antigens. J Immunol 156:2205
14. Hom SS, Rosenberg SA, Topalian SL (1993) Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas analysis by cytokine secretion. Cancer Immunol Immunother 36:1
15. Kirkin AF, Straten PT, Zeuthen J (1996) Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother 42:203
16. Le Drean E, Gervois N, Diez E, Semana G, Dreno B, Jotereau F (1995) HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4(+) melanoma-infiltrating lymphocytes. Eur J Immunol 25:2732
17. Nagata S (1996) Fas ligand and immune evasion. Nat Med 2:1306
18. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The fas counterattack: fas-mediated T cell killing by colon cancer cells expressing fas ligand. J Exp Med 184:1075
19. Ostrand-Rosenberg S (1994) Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 6:722
20. Pandolfino MC, Viret C, Gervois N, et al (1992) Specificity, t-cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. Eur J Immunol 22:1795
21. Pawelec G, Adibzadeh M, Bornhak S, et al (1996) The role of endogenous peptides in the direct pathway of alloreactivity to human MHC class II molecules expressed on CHO cells. Immunol Rev 154:155
22. Pawelec G, Kalbacher H, Pohla H, et al (1994) Requirements for stimulation or anergy induction in alloreactive human T cell clones. Cell Immunol 158:241
23. Pawelec G, Hambrecht A, Rehbein A, Adibzadeh M (1996) Interleukin 10 protects activated human T lymphocytes against growth factor withdrawal-induced cell death but only anti-fas antibody can prevent activation-induced cell death. Cytokine 8:877
24. Pawelec G, Max H, Halder T, et al (1996) BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells (bund at low frequency in the repertoire of normal donors. Blood 88:2118
25. Pawelec G, Zeuthen J, Kiessling R (1998) Escape from host-antitumor immunity. Crit Rev Oncog (in press)
26. Rammensee HG (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 7:85
27. Reeves SA, Chavez-Kappel C, Davis R, Rosenbloom M, Isreal MA (1992) Developmental regulation of annexin II (lipocortin II) in human brain and expression in high grade glioma. Cancer Res 52:6871
28. Robbins PF, Kawakami Y (1996) Human tumor antigens recognized by T cells. Curr Opin Immunol 8:628
29. Rötzschke O, Falk K, Wallny H-J, Faath S, Rammensee H-G (1990) Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 249:283
30. Sansom DM, Wilson A, Boshell M, Lewis J, Hall ND (1993) B7/CD28 But Not LFA-3/CD2 interactions can provide 3rd-party co-stimulation for human T-cell activation. Immunology 80:242
31. Schild H, Rötzschke O, Kalbacher H, Rammensee H-G (1990) Limit of T cell tolerance to self proteins by peptide presentation. Science 247:1587
32. Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, Topalian SL (1993) Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. Blood 82:1204
33. Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA (1991) Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 146:3674
34. Strand S, Hofmann WJ, Hug H, et al (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells a mechanism of immune evasion? Nature Med 2:1361
35. Ten Bosch GJA, Toornvliet AC, Friede T, Melief CJM, Leeksma OC (1995) Recognition of peptides corresponding to the joining region of p210(BCR-ABL) protein by human T cells. Leukemia 9:1344
36. Ten Bosch GJA, Joosten AM, Kessler JH, Melief CJM, Leeksma OC (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4(+)T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88:3522
37. Topalian SL (1994) MHC class II restricted tumor antigens and the role of CD4(+) T cells in cancer immunotherapy. Curr Opin Immunol 6:741
38. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91:9461
39. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 58:69
40. Topalian SL, Gonzales MI, Parkhurst M, et al (1996) Melanoma-specific CD4(+) T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183:1965
41. Vishwanatha JK, Chiang Y, Kumble KD, Holingsworth MA, Pour PM (1993) Enhanced expression of annexin TT in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 14:2575
42. Wallny H-J, Rammensee H-G (1990) Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 343:275